Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05279690
Other study ID # STUDY-21-01175
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date February 14, 2022
Est. completion date December 2024

Study information

Verified date February 2024
Source Icahn School of Medicine at Mount Sinai
Contact Natalie Lucas
Phone 929-489-5016
Email natalie.lucas@mssm.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This open-label, non-randomized study aims to determine the anti-inflammatory effect of colchicine on the reduction of peripheral blood CRP in patients with solid tumors or localized urothelial cancer. There are two cohorts, which will enroll separately and parallelly. Cohort 1 will include two successive groups with advanced/recurrent solid tumors (15 patients will receive low-dose colchicine and 15 for high-dose colchicine) who will receive 14 days of colchicine. In Cohort 2, 15 patients with post-radical surgery for high-risk clinically localized urothelial cancer will be enrolled. They will receive one 28-day cycle of colchicine. The primary outcome, post-treatment decline in CRP level, a continuous measure, will be defined as the maximum percentage decline from baseline in post-treatment CRP value within two weeks of colchicine (Cohort 1) or one cycle of colchicine (cohort 2), where the baseline value is measured before any treatment is initiated.


Recruitment information / eligibility

Status Recruiting
Enrollment 45
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria - Written informed consent and HIPAA authorization for release of personal health information prior to registration. NOTE: HIPAA authorization may be included in the informed consent or obtained separately. - Age = 18 years at the time of consent. - ECOG Performance Status of 0-1 within 28 days prior to registration. ECOG 2 is allowed for patients on Cohort 1. - Cohort 1: - Histological or cytologically confirmed solid tumor. - Metastatic or recurrent disease - Elevated peripheral blood CRP level (> 5 mg/L) documented on routine bloodwork within 14 days or registration. - Cohort 2: - History of urothelial cancer post radical cystectomy, nephroureterectomy, or ureterectomy - Eligible and planned for standard of care adjuvant nivolumab in the opinion of the treating investigator - Elevated peripheral blood CRP level (> 5 mg/L) documented on routine bloodwork at a minimum of 30 days and a maximum of 120 days after surgical resection and within 14 days prior to registration. - Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens in paraffin blocks (blocks preferred) or at least 15 unstained slides. If archival tissue is not available, enrollment will be considered on a case by case basis after discussion with the Principal Investigator. - Demonstrate adequate organ function as defined below. All screening labs to be obtained within 14 days prior to registration. - White blood cell (WBC) = 2.5 K/mm3 - Absolute Neutrophil Count (ANC) = 1.5 K/mm3 - Hemoglobin (Hgb) = 8 g/dL - Calculated GFR = 50 cc/min or creatinine = 1.5 mg/dl (The CKD-EPI equation will be used to calculate GFR) - Bilirubin = 1.5 × upper limit of normal (ULN) (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL) - Aspartate aminotransferase (AST) = 2.5 × ULN or < 5xULN for patients in Cohort 1 with liver metastases - Alanine aminotransferase (ALT) = 2.5 × ULN or < 5xULN for patients in Cohort 1 with liver metastases - Females of childbearing potential must have a negative serum pregnancy test within 14 days prior to registration. See section 5.5 for definition of childbearing potential. - Females of childbearing potential must be willing to abstain from heterosexual activity or to use an effective method(s) of contraception from the time of informed consent, during the study until after the last dose of study drug(s). Males must be willing to abstain from heterosexual activity or to use an effective method(s) of contraception from initiation of treatment until after the last dose of study drug(s). - HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration are eligible for this trial. - Patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, the HCV viral load must be undetectable to be eligible for this trial. - As determined by the enrolling physician or protocol designee, ability of the subject to understand and comply with study procedures for the entire length of the study. Exclusion Criteria - Already taking long term colchicine for any other reason. - Active infection requiring systemic therapy. - Pregnant or breastfeeding. - Prior cancer treatment must be completed at least 30 days prior to registration, or within 5 half-lives, and the subject must have recovered from all reversible acute toxic effects of the regimen (other than alopecia) to Grade = 1 or baseline. - Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen, per treating physician discretion, are not eligible for this trial. - Active central nervous system (CNS) metastases. - Treatment with any investigational drug within 30 days prior to registration. - Need for concomitant treatment with moderate or strong CYP3A4 inhibitors or P-gp inhibitors. - Rheumatoid arthritis, vasculitis, systemic lupus erythematosus, or other autoimmune condition requiring active systemic treatment. - Myocardial infarction within the prior last 6 months and/or = Class III New York Heart Association heart failure.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Colchicine
Patients will receive 14 days of colchicine in the absence of prohibitive toxicity of disease progression

Locations

Country Name City State
United States Icahn School of Medicine at Mount Sinai New York New York

Sponsors (1)

Lead Sponsor Collaborator
Icahn School of Medicine at Mount Sinai

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percent Change in Peripheral blood CRP level The primary outcome, post-treatment decline in peripheral blood CRP level, a continuous measure, will be defined as the maximum percent decline of post-treatment CRP from baseline obtained during the treatment period, where the baseline value is measured before any treatment initiated For a patient with an advanced/recurrent solid tumor who receive 2-weeks of treatment, it will be the maximum percentage decline during the 28 days of treatment. For a patient who receive colchicine less than 28 days, it will be the maximum percentage decline from baseline to the last day of treatment. Baseline and Within 28 days
See also
  Status Clinical Trial Phase
Recruiting NCT05919537 - Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation Phase 1
Active, not recruiting NCT04474470 - A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer Phase 1/Phase 2
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Terminated NCT05071183 - A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT05530200 - PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors. Phase 2
Active, not recruiting NCT04447651 - Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM)
Recruiting NCT04419532 - A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors Phase 1
Recruiting NCT04137900 - Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies Phase 1
Recruiting NCT04585750 - The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) Phase 1/Phase 2
Not yet recruiting NCT05028478 - A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies Phase 1/Phase 2
Recruiting NCT05471271 - IL-2 PET Imaging in Advanced Solid Tumours N/A
Recruiting NCT05867121 - A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors Phase 1
Active, not recruiting NCT03964727 - Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors Phase 2
Recruiting NCT06108050 - JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors Phase 1
Recruiting NCT05688280 - Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS Phase 1/Phase 2
Completed NCT04914117 - A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours Phase 1
Completed NCT00997529 - Mini Allo Stem Cell Transplantation for the Treatment of Solid Tumors N/A
Recruiting NCT04614740 - The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT06163391 - A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer Phase 1
Not yet recruiting NCT06415487 - ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) Phase 1